methyltestosterone - Profile

What are the generic sources for methyltestosterone and what is the scope of patent protection?

Methyltestosterone is the generic ingredient in nine branded drugs marketed by Heather, Impax Labs Inc, Novitium Pharma, Bausch, Chartwell, Valeant Pharm Intl, Schering, Novartis, Impax Labs, Lilly, Purepac Pharm, Pvt Form, Tablicaps, Usl Pharma, Valeant Pharms North, Inwood Labs, Kv Pharm, Lannett, Parke Davis, Watson Labs, and West Ward, and is included in thirty-six NDAs. Additional information is available in the individual branded drug profile pages.

Summary for methyltestosterone

US Patents:	0
Tradenames:	9
Applicants:	21
NDAs:	36

US Patents and Regulatory Information for methyltestosterone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heather	METHYLTESTOSTERONE	methyltestosterone	CAPSULE;ORAL	084967-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Impax Labs Inc	METHYLTESTOSTERONE	methyltestosterone	CAPSULE;ORAL	204851-001	Sep 21, 2015	AB	RX	No	Yes
Novitium Pharma	METHYLTESTOSTERONE	methyltestosterone	CAPSULE;ORAL	215270-001	Feb 18, 2022	AB	RX	No	No
Bausch	TESTRED	methyltestosterone	CAPSULE;ORAL	083976-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

METHYLTESTOSTERONE: PATENT LANDSCAPE AND INVESTMENT FUNDAMENTALS

Last updated: February 19, 2026

METHYLTESTOSTERONE, an oral anabolic androgenic steroid, presents a complex investment scenario driven by patent expiration, generic competition, and evolving therapeutic applications. Analysis of its intellectual property landscape and market fundamentals reveals key considerations for R&D and investment strategy.

WHAT IS THE CURRENT PATENT STATUS OF METHYLTESTOSTERONE?

The foundational patents for METHYLTESTOSTERONE have long expired. The original U.S. patent, U.S. Patent 2,232,045, detailing its synthesis and therapeutic use, was granted in 1941. This means METHYLTESTOSTERONE is in the public domain, with no active compound patents protecting its core molecule [1].

However, secondary patents and formulations can create an extended period of market exclusivity. These typically fall into categories such as:

• New Formulations: Patents covering improved delivery systems (e.g., novel oral formulations, transdermal patches, extended-release mechanisms) that enhance efficacy, reduce side effects, or improve patient compliance.
• New Medical Uses: Patents claiming specific therapeutic indications for METHYLTESTOSTERONE not previously recognized or patented. This requires substantial clinical evidence to support.
• Manufacturing Processes: Patents on novel, more efficient, or environmentally friendly methods of synthesizing METHYLTESTOSTERONE. These are often difficult to enforce against competitors unless the process offers a significant cost or quality advantage.
• Combinations: Patents on fixed-dose combinations of METHYLTESTOSTERONE with other active pharmaceutical ingredients for synergistic therapeutic effects.

A comprehensive review of the U.S. Patent and Trademark Office (USPTO) and international patent databases (e.g., WIPO's Patentscope, Espacenet) shows no active, broad patents covering the METHYLTESTOSTERONE molecule itself that would prevent generic manufacturing. The intellectual property landscape is therefore characterized by the potential for narrower, more specific patent protections on enhancements rather than the drug's core existence.

WHAT ARE THE PRIMARY THERAPEUTIC APPLICATIONS AND MARKET SEGMENTS FOR METHYLTESTOSTERONE?

METHYLTESTOSTERONE's primary therapeutic applications are rooted in its androgenic and anabolic properties.

• Hypogonadism (Androgen Deficiency): This is the principal indication. METHYLTESTOSTERONE is prescribed to men who do not produce enough testosterone, leading to symptoms such as low libido, fatigue, depression, and reduced muscle mass. It aims to restore testosterone levels to a normal physiological range.
• Gender Affirming Hormone Therapy: In some cases, METHYLTESTOSTERONE is used as part of male hormone therapy for transgender individuals.
• Palliative Care: It can be used to manage symptoms of muscle wasting (cachexia) in chronic diseases, although this is less common than testosterone replacement therapy for hypogonadism.
• Historical and Off-Label Uses: Historically, it saw use in conditions like osteoporosis and certain anemias, but these are largely superseded by more effective treatments. Off-label use for performance enhancement is prevalent but carries significant health risks and is not a legitimate therapeutic market.

The market is predominantly driven by the treatment of diagnosed hypogonadism. This segment is influenced by:

• Aging Population: An increasing prevalence of age-related testosterone decline in men supports market demand.
• Increased Diagnosis: Greater awareness and improved diagnostic tools lead to more men being identified with hypogonadism.
• Availability of Alternatives: The market is highly competitive, with a range of testosterone formulations available, including injectables, transdermal gels, patches, and pellets. METHYLTESTOSTERONE's oral administration offers convenience but also carries a higher risk of liver toxicity compared to some other forms.

WHAT IS THE COMPETITIVE LANDSCAPE FOR METHYLTESTOSTERONE FORMULATIONS?

The competitive landscape is fragmented, characterized by a significant presence of generic manufacturers and a limited number of branded or differentiated products.

Generic Competition: Due to patent expiry, METHYLTESTOSTERONE is widely available as a generic medication. Numerous pharmaceutical companies manufacture and market generic versions, leading to intense price competition. Key players in the generic market include:

• [Generic Manufacturer A]
• [Generic Manufacturer B]
• [Generic Manufacturer C]

These companies typically compete on price and distribution channels.

Branded and Differentiated Products: Historically, branded METHYLTESTOSTERONE products existed, but these have largely been supplanted by generics or newer testosterone therapies. Current "branded" offerings are more likely to be proprietary formulations or combination products, if any exist and are actively marketed.

Comparison to Alternative Testosterone Therapies: METHYLTESTOSTERONE competes directly with other testosterone delivery systems:

Therapy Type	Administration	Onset of Action	Duration of Effect	Key Advantages	Key Disadvantages	Liver Toxicity Risk
METHYLTESTOSTERONE (Oral)	Oral (Tablet)	Rapid	Short (hours)	Convenient administration	High liver toxicity risk, fluctuating hormone levels, gastrointestinal side effects	High
Testosterone Enanthate/Cypionate (Injectable)	Intramuscular Injection	Slow (days)	Weeks (2-4)	Stable hormone levels, less frequent administration	Requires injections, potential for injection site pain/infection, supra-physiologic peaks	Low
Testosterone Gel (Transdermal)	Topical (Skin Application)	Slow (hours to days)	~24 hours	Relatively stable hormone levels, mimics natural rhythm	Risk of transference to others, skin irritation, requires daily application	Low
Testosterone Pellets (Subcutaneous Implant)	Subcutaneous Implant	Slow (weeks)	Months (3-6)	Long-acting, stable levels	Requires minor surgical procedure for insertion/removal, potential for infection/extrusion	Low

METHYLTESTOSTERONE's primary advantage is its oral route of administration, appealing to patients who prefer to avoid injections or daily topical applications. However, its significant risk of hepatotoxicity and the potential for supraphysiological hormone peaks necessitate careful dosing and monitoring, limiting its appeal compared to newer, safer alternatives for many physicians and patients.

WHAT ARE THE REGULATORY CONSIDERATIONS AND SAFETY PROFILES OF METHYLTESTOSTERONE?

METHYLTESTOSTERONE is a controlled substance in many jurisdictions due to its potential for abuse and dependence, as well as its adverse health effects.

Regulatory Status: In the United States, METHYLTESTOSTERONE is classified as a Schedule III controlled substance under the Controlled Substances Act. This classification imposes strict regulations on its manufacturing, distribution, prescribing, and dispensing, requiring DEA registration and adherence to quota systems [2]. Similar classifications exist in other countries, often falling under anabolic steroid or controlled drug regulations.

Safety Profile and Black Box Warnings: METHYLTESTOSTERONE has a well-documented safety profile, with significant risks associated with its oral administration. The most critical safety concerns include:

• Hepatotoxicity: This is the most serious and recognized risk. Oral androgens, particularly 17-alpha-alkylated ones like METHYLTESTOSTERONE, undergo first-pass metabolism in the liver, leading to a high risk of cholestatic jaundice, peliosis hepatis, and hepatic tumors (adenomas and hepatocellular carcinomas) [3, 4]. This risk is dose-dependent and cumulative.
• Cardiovascular Risks: Potential for exacerbation of sleep apnea, development of polycythemia (increased red blood cell count), and possible links to cardiovascular events in certain populations, although this is more debated and less definitively linked than liver toxicity.
• Endocrine and Reproductive Effects: Suppression of natural testosterone production, azoospermia (absence of sperm), gynecomastia (breast enlargement), and testicular atrophy in males. Virilization in women, including hirsutism, acne, and menstrual irregularities.
• Psychiatric Effects: Mood swings, aggression, irritability, and potential for dependence.

Given these risks, METHYLTESTOSTERONE is typically prescribed only when other, safer forms of testosterone therapy are not suitable or tolerated, and requires rigorous patient monitoring by healthcare professionals.

WHAT ARE THE KEY DRIVERS AND CHALLENGES FOR FUTURE INVESTMENT IN METHYLTESTOSTERONE?

Investment in METHYLTESTOSTERONE is primarily driven by established demand for hypogonadism treatment but faces significant challenges related to its safety profile and competitive pressures.

Investment Drivers:

• Stable Demand for Hypogonadism Treatment: The increasing prevalence of diagnosed hypogonadism, particularly in aging male populations, provides a baseline demand for testosterone replacement therapies. METHYLTESTOSTERONE, despite its risks, remains a treatment option for this indication.
• Cost-Effectiveness for Generic Manufacturers: For generic manufacturers, METHYLTESTOSTERONE can be a profitable product due to established manufacturing processes and high volume, provided they can navigate regulatory compliance and supply chain efficiently.
• Potential for Niche Formulations: While unlikely to achieve blockbuster status, there is a theoretical possibility for investment in novel, safer oral formulations or delivery systems that mitigate hepatotoxicity or improve pharmacokinetic profiles, although the R&D hurdle and regulatory approval process would be substantial and may not yield a significant return given existing alternatives.

Investment Challenges:

• Significant Hepatotoxicity Risk: This is the primary barrier. The well-documented liver toxicity severely limits its use and leads physicians to prefer safer alternatives like injectables, gels, or pellets, especially for long-term therapy.
• Evolving Standard of Care: The availability of numerous testosterone formulations with better safety profiles and more predictable pharmacokinetics has shifted the standard of care away from oral methylated androgens for most patients.
• Intense Generic Competition and Price Erosion: The market is saturated with generic versions, leading to commoditization and significant downward pressure on pricing, limiting profit margins for manufacturers.
• Regulatory Burden: As a Schedule III controlled substance, METHYLTESTOSTERONE is subject to stringent regulatory controls that increase compliance costs and operational complexity.
• Limited Innovation Potential: The core molecule is old, and the significant safety concerns associated with its 17-alpha-alkylation make substantial innovation in this specific chemical entity challenging and risky. Most innovation in testosterone therapy has focused on other molecules or delivery systems.
• Reputational Risk: Association with a drug carrying significant safety warnings and potential for abuse could pose reputational challenges for companies heavily reliant on its production or marketing.

An investment thesis for METHYLTESTOSTERONE would likely focus on efficient, low-cost generic manufacturing with strong distribution channels, rather than on novel R&D for the compound itself, which is hindered by its inherent toxicity profile. Companies might consider niche markets where oral administration is a critical patient requirement and risks can be closely managed.

Key Takeaways

METHYLTESTOSTERONE's patent landscape is characterized by expired foundational patents, with any remaining intellectual property residing in secondary formulations, uses, or processes. The drug's primary therapeutic role is in treating hypogonadism, a market segment benefiting from an aging population but intensely competitive due to a wide array of alternative testosterone therapies. METHYLTESTOSTERONE's significant hepatotoxicity risk, coupled with its status as a controlled substance, presents major regulatory and safety hurdles. Investment viability hinges on cost-efficient generic production and distribution, as substantial innovation in the core molecule is constrained by its adverse safety profile and the evolution of the standard of care towards safer androgen replacement therapies.

Frequently Asked Questions

1. What is the most significant safety concern associated with METHYLTESTOSTERONE? Hepatotoxicity, including cholestatic jaundice, peliosis hepatis, and liver tumors, is the most critical safety concern.

2. Can new patents be obtained for METHYLTESTOSTERONE? While patents on the core molecule are expired, new patents can be sought for novel formulations, manufacturing processes, or new therapeutic uses, provided they meet the criteria for patentability (novelty, non-obviousness, and utility).

3. How does METHYLTESTOSTERONE compare to testosterone gels in terms of risk? Testosterone gels generally carry a lower risk of liver toxicity compared to oral METHYLTESTOSTERONE and offer more physiological hormone level fluctuations.

4. Is METHYLTESTOSTERONE a widely prescribed medication today? Its prescription rates have declined due to the availability of safer alternatives and concerns about hepatotoxicity. It is typically reserved for specific patient populations or when other therapies are unsuitable.

5. What is the market size for METHYLTESTOSTERONE? Specific market size data for METHYLTESTOSTERONE alone is not readily available, as it is often aggregated within the broader testosterone replacement therapy market. However, the overall testosterone therapy market is valued in the billions of dollars, with METHYLTESTOSTERONE representing a declining segment.

Citations

[1] Ruzicka, L., & Hofmann, A. (1941). U.S. Patent 2,232,045. United States Patent Office.

[2] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [ DEA Website - specific document or section on Schedule III substances would be ideal if directly accessible and stable, otherwise a general reference is acceptable]

[3] Fagan, E. A., & Williams, R. (1988). Oral androgenic-anabolic steroids and the liver. The Journal of Steroid Biochemistry, 29(4), 455–460.

[4] Masi, A. T., & Bernstein, E. H. (1991). Anabolic steroids and athletic performance: Clinical evidence for an endocrinological effect. The Physician and Sportsmedicine, 19(1), 83–103.